MedTrace Logo

Vertical Soft Tissue Augmentation With CTG vs ADM

NCT05729607 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2025-09-18

No results posted yet for this study

Summary

The study aims at comparing two different approaches for vertical soft tissue augmentation at implant sites exhibiting soft tissue dehiscences: autogenous connective tissue graft vs acellular dermal matrix + enamel matrix derivative

Conditions

  • Implant Complication

Interventions

PROCEDURE

Vertical soft tissue augmentation

Vertical soft tissue augmentation with autogenous connective tissue graft (CTG)

PROCEDURE

Vertical soft tissue augmentation

Vertical soft tissue augmentation with acellular dermal matrix (ADM) and enamel matrix derivative (EMD)

Sponsors & Collaborators

  • Harvard Medical School (HMS and HSDM)

    lead OTHER

Principal Investigators

  • Lorenzo Tavelli, DDS, MS · Harvard School of Dental Medicine, Boston, USA

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-05-26
Primary Completion
2027-02-27
Completion
2027-11-27

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05729607 on ClinicalTrials.gov